After completing the development of the new pKa model, we retrained almost all other predictive models in order to capture the benefit of the more accurate ionization description. This means that our already established lead as the most accurate molecular-structure-to-property prediction program has just been pushed further ahead of the competition.
“ADMET Predictor has been compared to similar software offerings from many other companies in a number of scientific journal articles by independent third parties and has been consistently ranked #1 in predictive accuracy. The extension of the ‘chemical coverage space’ in our pKa model has resulted in an increase in the number of chemical and consumer goods companies requesting evaluations. We anticipate this will help us continue to penetrate these markets.
It's a long shot at best. Royalties for inventions and patents vary considerably... Royalties are even influenced by the ability and financial worth of the licensee. You can find probably more than you care to know at this link:
.pli dot edu/product_files/EN00000000000629/89238 dot pdf
Simulations Plus, Inc. (SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that its second NCE (new chemical entity) initiative, which involved using Simulations Plus software to design molecules to inhibit COX-2, has been a success as determined by synthesis and testing by a third-party lab. Three of the four molecules it has designed are potent inhibitors of both cyclooxygenase-2 (COX-2) and COX-1 enzymes. The fourth inhibits COX-2 but only weakly inhibits COX-1.
Dr. Robert Clark, director of cheminformatics sciences for Simulations Plus, said: “We’re very pleased to report that our second NCE project has again demonstrated that our ADMET Design Suite™ (ADMET Predictor™, MedChem Studio™, and MedChem Designer™, supplemented by GastroPlus™ simulations) provides tools that can rapidly and inexpensively generate new lead molecules with affinity for selected targets. This project was more challenging than the malaria NCE project we completed two years ago because this time our goal was to inhibit two targets with a single molecule while also providing good ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties. Southern Research Institute in Birmingham, Alabama, performed the chemical synthesis and Cerep in Redmond, Washington, performed the COX-2 and COX-1 assays.”
The fact that these molecules were designed using only our own software suite is a testament to the capabilities provided by these powerful programs.”
You really need the same tools that the FDA is using to judge the efficacy and risks of your submission.
Simulations Plus, Inc. (SLP), a leading provider of software for pharmaceutical discovery and development, announced that it has signed a five-year research collaboration agreement (RCA) with the U.S. Food and Drug Administration (FDA) to work together to determine the value of mechanistic absorption modeling (“MAM”) in developing predictive and robust in vitro-in vivo correlations (IVIVCs). The collaboration will examine how the use of MAM can provide additional insight and greater accuracy with regards to prediction of complex drug absorption characteristics. The ultimate goal is to facilitate drug and generic product development by decreasing the regulatory burden through adequate modeling approaches.
Under the agreement, Simulations Plus will provide licenses for the Company’s GastroPlus™ simulation software to model in vivo data representative of challenging absorption characteristics to the FDA's Office of Testing and Research located in the Center for Drug Evaluation and Research Office of Pharmaceutical Science. During the first year, the Company will provide training to FDA investigators regarding the underlying mathematical models. During the course of the collaboration, ideas and recommendations will be exchanged between the FDA and the Company that aim to improve MAM. The collaborators plan to make results from this research available to the public.
I haven't seen any news. We've had a fairly strong price increase recently so it may just be a " reversion to the mean" type price move. Part of it may also be the fact that the dividend was paid this past Monday so there are probably some sellers that were waiting on the payout.
Howard Halpern has provided an update to the Taglich research report. The rating continues to be " Speculative Buy " with a $6.10 price target. Yahoo still does not allow links to be posted so you can find this report by doing a Google for Taglich Brothers.
Not too long ago when the stock was at 4.75 the yield was over 5%. With the recent advance the same dividend now provides a yield of a little over 4%. Either way it's a bargain... I like the dividend but, the real value here is the future of the business. I mean, here we have scientists and chemists that are writing code for software that provides answers for some of the most expensive and complex problems that the business community needs to resolve. These same engineering professionals end up being the sales force and then the teachers for the drug discovery customers. The new NCE work as well as the aerodynamic force modeling that Walt talked about in the last CC are exciting areas for the future. Walt is an aerospace engineer from Auburn University and worked in rocket engine modeling before he started SLP so this is not foreign territory for him. Although the dividend is nice, the future at SLP is worth much more.
SLP management continues to do all the right stuff that grows the company. Major software upgrades will be a "must have" item for anyone in the drug discovery business. If the FDA is using a SLP product you can be certain that anyone expecting to have their hard work reviewed by them that they will be sure they are using the latest and best available. Also, look at the workshop schedule... This is a serious venue for picking up new customers. All the right things are taking place at SLP and investors will continue to purchase the stock.
I continue to hold all of my shares.
ADMET Predictor is sophisticated, yet very easy to use, computer software for advanced predictive modeling of ADMET properties. The "ADMET" acronym is commonly used in the pharmaceutical industry to indicate all the phenomena associated with Absorption, Distribution, Metabolism, Elimination, and Toxicity of chemical substances in the human body. ADMET Predictor not only rapidly estimates a number of vital ADMET properties (listed below) from molecular structures, but is also capable of building predictive models of new properties from user's data via its integrated ADMET Modeler™ module. The program predictions can be further utilized as inputs for our software products GastroPlus™ and MedChem Studio™, or used internally by a flexible screening filters ADMET Risk that can include any combination of predicted properties. All predictions for single structures, as well as structure editing, can also be directly accessed from MedChem Designer™.
• The new pKa model developed in collaboration with Bayer HealthCare is now available for everyone to use. The "applicability domain" has been expanded through the addition of thousands of Bayer compounds. What does this mean for you? The top-rated property models become more accurate, leading to better screening results, inputs for GastroPlus™ simulations, etc...
• All predictive models were retrained.
• New models added to predict P-gp inhibition and chemical biodegradability.
• Classification models created with ADMET Modeler™ automatically include confidence estimates for each prediction. Error rate and uncertainty, along with prediction and error distributions graphs are included as part of automatic confidence analysis.
• New algorithms to select the best artificial neural network model have been implemented.
• "Soft" decision boundaries can now be used in ADMET Risk™ instead of hard cutoffs.
• and more!
I started a message board on I-Hub several years ago... You think this is slow at Yahoo... Investorshub has only a fraction of the activity. Anyway, I-Hub has a board already set up... all it needs is participation. I post at both locations although it's been a while since I posted at I-Hub.
If you look at the "Major holders" at Yahoo under "Ownership" and add up what the insiders, mutual funds and institutional are actually holding you come up with 83%... That only leaves 17% for you and me :-) It looks like they have a sizeable amount already. $10 is another important threshold, I'm expecting some activity when we cross that.
Last year SLP reported on the 14th so we should be seeing the report very soon. Given the preliminary sales numbers released we should expect a very nice earnings report. I'm guessing maybe .048 per share in earnings. This would be about a 34% increase over last year. There are several variables that can make this go either way... taxes and R&D for example. But... I'm expecting a nice bottom line that should keep the stock price going in the right direction and also keep the dividend safe. Speaking of dividends... The next dividend announcement may catch investors by surprise. The next dividend ( if the board votes for one ) could be higher than what is generally expected. We have seen recent increases and we are past the dividends that were pulled in early in 2012 for the lower tax rate so I'm looking forward for the next announcement. IF, and that's a big IF, the board votes for a .07 per share dividend, that along with a solid earnings report should put a solid floor under the current price. With a price of $5.00 a share a .07 quarterly dividend puts the yield will ahead of 5%.
SLP continues to be an excellent investment.
Read the news. A sleazy law firm is investigating them for providing a stock option plan used to retain the top talent that is making SLP such a great investment. It's extortion, they hope that SLP will settle and pay up to avoid a legal exercise.
Do a google search on Faruqi & Faruqi. Many links re their business style. Also, read the one about them being sued for sexual harassment.
and you can easily see what this low life is all about. They run around filing law suits against companies and "settle" for money because it's cheaper than to fight a bogus claim in court. I tried to post a link about their rotten business approach but Yahoo makes it impossible to post anything that resembles a link.
Thank you for your many years of tireless dedication and commitment. Your quest for perfection and honesty is reflected in the financial condition and reporting of Simulations Plus... an example that is rare to find in public companies. The Simulation Plus shareholders give you a very big thank you and hope that your retirement is enjoyable.
What looked like a sales and earnings shortfall has already been booked in Q1. A large order slipped from Q4 into Q1 so we should see continued sales and earnings improvement in the coming reports. There are several new and positive items discussed in the conference call... There have been several cases where SLP software results have been accepted by regulatory agencies and as a result physical drug trials were waived and not required. The drug discovery industry is embracing software solutions and SLP is providing what they need. This is an exciting time to be invested in this industry and SLP has a leadership position. I encourage everyone to listen to the conference call replay that should be available on the SLP web site later today or tomorrow. Also, Seeking Alpha has a conference call transcript.